Skip to content

Exploratory analysis of biomarker related to RO4987655 in patients with advanced solid tumors

Exploratory analysis of biomarker related to RO4987655 in patients with advanced solid tumors - Exploratory analysis of biomarker related to RO4987655 in patients with advanced solid tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000011157
Enrollment
8
Registered
2013-07-10
Start date
2013-05-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with advanced solid tumors

Interventions

None listed

Sponsors

National Cancer Center Hospital
Lead Sponsor
Chugai Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who enrolled into phase I clinical trial in patients with advanced solid tumors (JapicCTI-111490), received RO4987655, and consented to provide archival tumor tissue or biopsy samples.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Identification of biomarker related to efficacy of RO4987655

Countries

Japan

Contacts

Public ContactYasuhide Yamada

National Cancer Center Hospital Division of Gastrointestinal Oncology

yayamada@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026